Rheumatoid Arthritis Global Market Research Report: 2016 Edition | AbbVie, JNJ, Amgen Inc., Pfizer Inc.

Researchmoz added Most up-to-date research on "Global Rheumatoid Arthritis Market Report: 2016 Edition" to its huge collection of research reports.

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=746067

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.

Table of Content

1. Market Overview
1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-rheumatoid-arthritis-market-report-2016-edition-report.html/toc

2 Global Market
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics

3. The U.S. Market
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population

4. Market Dynamics
4.1 Key Trends
4.1.1 Increasing Competition from Anti IL 6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost

5. Competitive Landscape
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share

Continue...

Global Rheumatoid Arthritis Market Key Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "Global Rheumatoid Arthritis Market Report: 2016 Edition" to its huge collection of research reports.

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=746067

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.

Table of Content

1. Market Overview1.1 Arthritis
1.2 Types of Arthritis
1.2 Rheumatoid Arthritis
1.3 Causes
1.4 Stage
1.5 Diagnosis
1.6 Treatment Options

2 Global Market
2.1 Global Rheumatoid Arthritis Market by Value
2.2 Global Rheumatoid Arthritis Market by Drug Class
2.3 Global Rheumatoid Market Share by Drug
2.4 Global Rheumatoid Arthritis Market Share by Biologics

3. The U.S. Market
3.1 The US Rheumatoid Arthritis Market by Value
3.2 The US Rheumatoid Arthritis Patient Prevalence
3.3 The US Rheumatoid Arthritis Patient Penetration
3.4 The US Rheumatoid Arthritis Anti TNF Population
3.5 The US Rheumatoid Arthritis Biologics Population

4. Market Dynamics
4.1 Key Trends
4.1.1 Increasing Competition from Anti IL 6 Drugs
4.1.2 Rising FDA Approvals to Rheumatoid Arthritis Drugs
4.1.3 Auto Injectors for Rheumatoid Arthritis
4.1.4 Use of Complementary and Alternative Medicines (CAMs)
4.1.5 Increasing Biosimilars for Rheumatoid Arthritis
4.2 Growth Drivers
4.2.1 Increasing Female Population Worldwide
4.2.2 Escalating Global Ageing Population
4.2.3 Rising Global Health Care Expenditure
4.2.4 Rising Cigarette Consumption
4.2.5 Increasing Obese Population
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.3 High R&D Cost

5. Competitive Landscape
5.1 Global Market
5.1.1 Rheumatoid Arthritis Market Share by Company
5.1.2 Rheumatoid Arthritis Market Competition by Anti TNF
5.1.3 Rheumatoid Arthritis Competition by Biologics
5.2 The US Market
5.2.1 Rheumatoid Arthritis Brand (Company) Share

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=746067

Recent Study on Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Researchmoz added Most up-to-date research on "Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation" to its huge collection of research reports.
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=799450

Scope

- Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
- What is the pathophysiology of RA?
- Which products and therapeutic strategies dominate the clinical and commercial landscapes?
- What are the most significant unmet needs within the RA market?
- Considerable diversification from current market trends is evident within the RA pipeline.
- Which molecular targets are most prominent within the pipeline?
- What proportion of pipeline products are first in class?
- Which first-in-class targets are most promising?
- Deal values for licensing and co-development deals vary considerably.
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

This report will allow you to:
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=799450